Join
Live feed
·
PRReleasevia Quantisnow
PureTech Health plc logo

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

ByQuantisnow·Wall Street's wire, on your screen.
PRTC· PureTech Health plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRTC (PureTech Health plc) and more on Quantisnow.